The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Radiopharmaceuticals in Nuclear Medicine-Global Market Insights and Sales Trends 2025
Synopsis
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceuticals in Nuclear Medicine market size is expected to reach US$ 6988.2 million by 2029, growing at a CAGR of 5.0% from 2023 to 2029. The market is mainly driven by the significant applications of Radiopharmaceuticals in Nuclear Medicine in various end use industries. The expanding demands from the Diagnostic Application, Therapeutic Application, Research and Pharmaceutical, are propelling Radiopharmaceuticals in Nuclear Medicine market. Diagnostic Radiopharmaceuticals, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapy Radiopharmaceuticals segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Radiopharmaceuticals in Nuclear Medicine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Radiopharmaceuticals in Nuclear Medicine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Radiopharmaceuticals in Nuclear Medicine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Radiopharmaceuticals in Nuclear Medicine covered in this report include Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group and Isotec, Inc. (Sigma-Aldrich), etc.
The global Radiopharmaceuticals in Nuclear Medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Global Radiopharmaceuticals in Nuclear Medicine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Radiopharmaceuticals in Nuclear Medicine market, Segment by Type:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Global Radiopharmaceuticals in Nuclear Medicine market, by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceuticals in Nuclear Medicine market size is expected to reach US$ 6988.2 million by 2029, growing at a CAGR of 5.0% from 2023 to 2029. The market is mainly driven by the significant applications of Radiopharmaceuticals in Nuclear Medicine in various end use industries. The expanding demands from the Diagnostic Application, Therapeutic Application, Research and Pharmaceutical, are propelling Radiopharmaceuticals in Nuclear Medicine market. Diagnostic Radiopharmaceuticals, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapy Radiopharmaceuticals segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Radiopharmaceuticals in Nuclear Medicine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Radiopharmaceuticals in Nuclear Medicine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Radiopharmaceuticals in Nuclear Medicine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Radiopharmaceuticals in Nuclear Medicine covered in this report include Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group and Isotec, Inc. (Sigma-Aldrich), etc.
The global Radiopharmaceuticals in Nuclear Medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Global Radiopharmaceuticals in Nuclear Medicine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Radiopharmaceuticals in Nuclear Medicine market, Segment by Type:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Global Radiopharmaceuticals in Nuclear Medicine market, by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Radiopharmaceuticals in Nuclear Medicine Market Overview
1.1 Radiopharmaceuticals in Nuclear Medicine Product Overview
1.2 Radiopharmaceuticals in Nuclear Medicine Market Segment by Type
1.2.1 Diagnostic Radiopharmaceuticals
1.2.2 Therapy Radiopharmaceuticals
1.2.3 Enriched Stable Isotopes
1.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Overview by Type (2018-2029)
1.3.2 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Type (2018-2023)
2 Global Radiopharmaceuticals in Nuclear Medicine Market Competition by Company
2.1 Global Top Players by Radiopharmaceuticals in Nuclear Medicine Sales (2018-2023)
2.2 Global Top Players by Radiopharmaceuticals in Nuclear Medicine Revenue (2018-2023)
2.3 Global Top Players by Radiopharmaceuticals in Nuclear Medicine Price (2018-2023)
2.4 Global Top Manufacturers Radiopharmaceuticals in Nuclear Medicine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
2.5.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Radiopharmaceuticals in Nuclear Medicine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2022)
2.7 Date of Key Manufacturers Enter into Radiopharmaceuticals in Nuclear Medicine Market
2.8 Key Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Radiopharmaceuticals in Nuclear Medicine Status and Outlook by Region
3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Region
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2018-2023)
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2018-2023)
3.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Region
3.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2024-2029)
3.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2024-2029)
3.3.3 Global Radiopharmaceuticals in Nuclear Medicine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Radiopharmaceuticals in Nuclear Medicine by Application
4.1 Radiopharmaceuticals in Nuclear Medicine Market Segment by Application
4.1.1 Diagnostic Application
4.1.2 Therapeutic Application
4.1.3 Research
4.1.4 Pharmaceutical
4.1.5 Other
4.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Overview by Application (2018-2029)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Breakdown by Application (2018-2023)
5 North America Radiopharmaceuticals in Nuclear Medicine by Country
5.1 North America Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Country
5.1.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2018-2023)
5.1.3 North America Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2018-2023)
5.2 North America Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Country
5.2.1 North America Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2024-2029)
5.2.2 North America Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2024-2029)
6 Europe Radiopharmaceuticals in Nuclear Medicine by Country
6.1 Europe Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Country
6.1.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2018-2023)
6.1.3 Europe Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2018-2023)
6.2 Europe Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Country
6.2.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2024-2029)
6.2.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2024-2029)
7 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine by Region
7.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Region
7.1.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Region
7.2.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2024-2029)
8 Latin America Radiopharmaceuticals in Nuclear Medicine by Country
8.1 Latin America Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Country
8.1.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2018-2023)
8.2 Latin America Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Country
8.2.1 Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2024-2029)
9 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine by Country
9.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Country
9.1.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Country
9.2.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bracco Imaging S.P.A.
10.1.1 Bracco Imaging S.P.A. Company Information
10.1.2 Bracco Imaging S.P.A. Introduction and Business Overview
10.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.1.5 Bracco Imaging S.P.A. Recent Development
10.2 Cambridge Isotope Laboratories, Inc.
10.2.1 Cambridge Isotope Laboratories, Inc. Company Information
10.2.2 Cambridge Isotope Laboratories, Inc. Introduction and Business Overview
10.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.2.5 Cambridge Isotope Laboratories, Inc. Recent Development
10.3 Cardinal Health, Inc.
10.3.1 Cardinal Health, Inc. Company Information
10.3.2 Cardinal Health, Inc. Introduction and Business Overview
10.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.3.5 Cardinal Health, Inc. Recent Development
10.4 Covidien, Plc
10.4.1 Covidien, Plc Company Information
10.4.2 Covidien, Plc Introduction and Business Overview
10.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Products Offered
10.4.5 Covidien, Plc Recent Development
10.5 Eczacibasi-Monrol
10.5.1 Eczacibasi-Monrol Company Information
10.5.2 Eczacibasi-Monrol Introduction and Business Overview
10.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Products Offered
10.5.5 Eczacibasi-Monrol Recent Development
10.6 Fujifilm Holdings Corporation
10.6.1 Fujifilm Holdings Corporation Company Information
10.6.2 Fujifilm Holdings Corporation Introduction and Business Overview
10.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Products Offered
10.6.5 Fujifilm Holdings Corporation Recent Development
10.7 GE Healthcare (Subsidiary Of General Electric Company)
10.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Information
10.7.2 GE Healthcare (Subsidiary Of General Electric Company) Introduction and Business Overview
10.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Products Offered
10.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Development
10.8 IBA Group
10.8.1 IBA Group Company Information
10.8.2 IBA Group Introduction and Business Overview
10.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Products Offered
10.8.5 IBA Group Recent Development
10.9 Isotec, Inc. (Sigma-Aldrich)
10.9.1 Isotec, Inc. (Sigma-Aldrich) Company Information
10.9.2 Isotec, Inc. (Sigma-Aldrich) Introduction and Business Overview
10.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Products Offered
10.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Development
10.10 Lantheus Medical Imaging, Inc.
10.10.1 Lantheus Medical Imaging, Inc. Company Information
10.10.2 Lantheus Medical Imaging, Inc. Introduction and Business Overview
10.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.10.5 Lantheus Medical Imaging, Inc. Recent Development
10.11 Nordion, Inc.
10.11.1 Nordion, Inc. Company Information
10.11.2 Nordion, Inc. Introduction and Business Overview
10.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.11.5 Nordion, Inc. Recent Development
10.12 Ntp Radioisotopes (Pty), Ltd.
10.12.1 Ntp Radioisotopes (Pty), Ltd. Company Information
10.12.2 Ntp Radioisotopes (Pty), Ltd. Introduction and Business Overview
10.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Development
10.13 Siemens Healthcare (Subsidiary Of Siemens AG)
10.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Information
10.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Introduction and Business Overview
10.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Products Offered
10.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Development
10.14 Taiyo Nippon Sanso Corporation
10.14.1 Taiyo Nippon Sanso Corporation Company Information
10.14.2 Taiyo Nippon Sanso Corporation Introduction and Business Overview
10.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Products Offered
10.14.5 Taiyo Nippon Sanso Corporation Recent Development
10.15 Urenco Limited
10.15.1 Urenco Limited Company Information
10.15.2 Urenco Limited Introduction and Business Overview
10.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Products Offered
10.15.5 Urenco Limited Recent Development
10.16 Rotem Industries, Ltd., Inc.
10.16.1 Rotem Industries, Ltd., Inc. Company Information
10.16.2 Rotem Industries, Ltd., Inc. Introduction and Business Overview
10.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.16.5 Rotem Industries, Ltd., Inc. Recent Development
10.17 Australian Nuclear Association And Technology Organization (ANSTO)
10.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Information
10.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Introduction and Business Overview
10.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Products Offered
10.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Development
10.18 Board of Radiation And Isotope Technology (BRIT)
10.18.1 Board of Radiation And Isotope Technology (BRIT) Company Information
10.18.2 Board of Radiation And Isotope Technology (BRIT) Introduction and Business Overview
10.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Products Offered
10.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Development
10.19 Institute of Atomic Energy Polatom Radioisotope Centre
10.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Information
10.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Introduction and Business Overview
10.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Products Offered
10.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Development
10.20 Institute of Isotopes Co., Ltd.
10.20.1 Institute of Isotopes Co., Ltd. Company Information
10.20.2 Institute of Isotopes Co., Ltd. Introduction and Business Overview
10.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Products Offered
10.20.5 Institute of Isotopes Co., Ltd. Recent Development
10.21 Institute Of Radioelement (IRE)
10.21.1 Institute Of Radioelement (IRE) Company Information
10.21.2 Institute Of Radioelement (IRE) Introduction and Business Overview
10.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2018-2023)
10.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Products Offered
10.21.5 Institute Of Radioelement (IRE) Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Radiopharmaceuticals in Nuclear Medicine Industrial Chain Analysis
11.4 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
11.4.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
11.4.2 Radiopharmaceuticals in Nuclear Medicine Market Drivers
11.4.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
11.4.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Radiopharmaceuticals in Nuclear Medicine Distributors
12.3 Radiopharmaceuticals in Nuclear Medicine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
